The Limitations of Dopaminergic Therapies in Advanced Parkinson’s Disease
References
- Pirtošek Z, Bajenaru O, Kovács N, et al. Update on the management of Parkinson’s disease for general neurologists. Parkinsons Dis. 2020;2020:9131474.
- Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16(3):448–458.
- Nyholm D, Jost WH. Levodopa–entacapone–carbidopa intestinal gel infusion in advanced Parkinson’s disease: real-world experience and practical guidance. Ther Adv Neurol Disord. 2022;15:17562864221108018.
- Antonini A, D’Onofrio V, Guerra A. Current and novel infusion therapies for patients with Parkinson’s disease. J Neural Transm (Vienna). 2023;130(9):1349–1358.
- Szász JA, Szatmári S, Constantin V, et al. Decision-making and duration to accept device-aided therapy in advanced Parkinson’s disease: retrospective data from an Eastern European center with high patient turnover. Orv Hetil. 2021;162(21):839–847.
- Odin P, Ray Chaudhuri K, Slevin JT, et al. Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson’s disease: consensus from an international survey and discussion program. Parkinsonism Relat Disord. 2015;21(10):1133–1144.
- Szász JA, Constantin VA, Orbán-Kis K, et al. Profile of patients with advanced Parkinson’s disease suitable for device-aided therapies: retrospective data of a large cohort of Romanian patients. Neuropsychiatr Dis Treat. 2019;15:3187–3195.
- Szasz JA, Constantin VA, Orban-Kis K, et al. Levodopacarbidopa intestinal gel in advanced Parkinson's disease: observations and dilemmas after 10 years of real-life experience. Pharmaceutics. 2022;14(6):1115.
- Fasano A, Gurevich T, Jech R, et al. Concomitant medication usage with levodopa-carbidopa intestinal gel: results from the COSMOS study. Mov Disord. 2021;36:1–11.
- Kuoppamäki M, Leinonen M, Poewe W. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson’s disease patients with wearing-off. J Neural Transm (Vienna). 2015;122(12):1709–1714.
- Viljaharju V, Mertsalmi T, Pauls KAM, et al. Levodopaentacapone-carbidopa intestinal gel treatment in advanced Parkinson’s disease: a single-center study of 30 patients. Mov Disord Clin Pract. 2023;10:1–7.
DOI: https://doi.org/10.2478/orvtudert-2025-0009 | Journal eISSN: 2537-5059 | Journal ISSN: 1453-0953
Language: English
Page range: 113 - 120
Published on: Jul 2, 2026
Published by: Transylvanian Museum Society
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Related subjects:
© 2026 Szász Róbert Máté, Orbán-Kis Károly, Graur Medárd, Kis János Krisztián, Bíró Konrád, Szász József Attila, Szatmári Szabolcs, published by Transylvanian Museum Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.